Wall Street brokerages forecast that Allena Pharmaceuticals Inc (NASDAQ:ALNA) will report earnings of ($0.27) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Allena Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.19). Allena Pharmaceuticals reported earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The company is expected to issue its next quarterly earnings report on Wednesday, August 5th.
Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.14.
A number of large investors have recently added to or reduced their stakes in ALNA. Algert Global LLC acquired a new stake in shares of Allena Pharmaceuticals in the 4th quarter valued at approximately $101,000. Banco Bilbao Vizcaya Argentaria S.A. acquired a new stake in shares of Allena Pharmaceuticals in the 4th quarter valued at approximately $104,000. Wedbush Securities Inc. boosted its holdings in shares of Allena Pharmaceuticals by 95.5% in the 4th quarter. Wedbush Securities Inc. now owns 50,150 shares of the company’s stock valued at $137,000 after buying an additional 24,500 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Allena Pharmaceuticals by 103.0% in the 4th quarter. Geode Capital Management LLC now owns 105,854 shares of the company’s stock valued at $288,000 after buying an additional 53,719 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Allena Pharmaceuticals by 91.2% in the 4th quarter. Renaissance Technologies LLC now owns 241,700 shares of the company’s stock valued at $660,000 after buying an additional 115,300 shares during the last quarter. 58.39% of the stock is owned by hedge funds and other institutional investors.
Allena Pharmaceuticals stock traded down $0.01 during trading hours on Friday, reaching $1.88. 62,839 shares of the company’s stock traded hands, compared to its average volume of 312,170. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.84 and a current ratio of 2.84. Allena Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $6.30. The firm has a market capitalization of $46.76 million, a price-to-earnings ratio of -0.99 and a beta of 2.93. The firm’s 50 day moving average is $1.52 and its 200-day moving average is $2.04.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Read More: 52-Week High/Low Prices For Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.